By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs
Summary
An oral dissolving strip (ODS) and an orally disintegrating tablet (ODT) both break apart in the mouth without water, but they handle the dose differently afterward. The FDA defines an ODT as a tablet that disintegrates within about 30 seconds and is then swallowed, so most of its dose is absorbed in the gut. An ODS is a thin polymer film that can hold directed contact with the oral mucosa. In one buccal study, 100 seconds of mucosal contact raised midazolam bioavailability from 27.8 percent to 66.1 percent. For MIHIYO Labs, the film is also more flexible and less fragile.
Oral dissolving strip vs orally disintegrating tablet: which is the closer call?
This is the closest comparison in the whole dosage-form series, and I want to be honest about why. An orally disintegrating tablet (ODT) is a tablet engineered to fall apart in the mouth in seconds without water. An oral dissolving strip (ODS) is a thin polymer film that does the same. From the outside they look like solutions to the same problem: dosing without a glass of water.
The difference is what happens in the few seconds after the form breaks apart. An ODT disintegrates and is then swallowed, so the dispersed particles travel to the gut and are absorbed the way any swallowed tablet would be. A film can stay flat against the cheek or under the tongue and hold contact with the mucosa for part of that window. When I formulate, that retention step is the variable I care about most, because it is the one I can design around.
How an ODT and an ODS each behave in the mouth
An ODT is defined by its disintegration, not by where the drug ends up. The U.S. Food and Drug Administration's 2008 guidance describes an orally disintegrating tablet as a solid dosage form that disintegrates rapidly in the mouth, and it recommends an in vitro disintegration time of roughly 30 seconds or less.1 In practice, real tablets span a wider range. When Koner and colleagues measured in vivo disintegration across nine formulations in 35 volunteers, times ran from about 10 to 150 seconds, and the standard pharmacopeial bench test correlated poorly with what actually happened in the mouth.6 So "disintegrates fast" is the design intent; the lived experience varies by formulation.
The key point is what comes next. Once an ODT has disintegrated, the patient swallows the resulting suspension. From that moment it is ordinary gastrointestinal absorption, with the same first-pass metabolism any swallowed dose faces. First-pass metabolism is the loss of a drug as it passes through the gut wall and liver before reaching the general circulation. The ODT format solves the swallowing problem, not the absorption-route problem.
An oral dissolving strip starts from a different geometry. Hoffmann and colleagues describe orodispersible films as thin polymer matrices that hydrate and disintegrate in saliva in roughly 30 to 60 seconds.2 Because the film is flat and adheres briefly to wet tissue, part of the dose can sit in contact with the oral mucosa rather than being swallowed immediately. Jacob and coauthors describe film- and patch-based buccal systems as platforms designed to maintain intimate association with the mucosa and prolong residence at the absorption site.4 That is the structural reason a film and a tablet are not interchangeable, even when both melt in the mouth.
What the comparison looks like across the dimensions that matter
For this topic the table is the spine of the argument. Four concrete dimensions separate the two forms: where the dose goes, how robust the form is, how portable it is, and how much directed mucosal contact it can achieve.
| Dimension | Orally disintegrating tablet (ODT) | Oral dissolving strip (ODS) | Source |
|---|---|---|---|
| Disintegration without water | FDA recommends ~30 s or less; measured in vivo ~10 to 150 s across formulations | Hydrates and disintegrates in saliva in about 30 to 60 s | FDA, 2008; Koner et al., 2019; Hoffmann et al., 2011 |
| Where the dose goes | Disintegrates, then the particles are swallowed; mostly gastrointestinal absorption with first-pass | Thin film can hold directed mucosal contact; part of the dose can cross before swallowing | FDA, 2008; Jacob et al., 2021; Bartlett & van der Voort Maarschalk, 2012 |
| Mechanical robustness | Low compression force and porous matrix make many ODTs fragile and friable; need protective dry packaging | Flexible polymer film bends rather than crumbles; flat sealed pouch | Ghourichay et al., 2021; Slavkova & Breitkreutz, 2015 |
| Contact-time effect | Limited directed mucosal contact because particles are swallowed quickly | 100 s of buccal contact raised midazolam bioavailability from 27.8% to 66.1% | Grass et al., 2021 |
| Acceptability / portability | Established, well-accepted format; rigid and moisture-sensitive in the pack | Thin, dry, flat unit dose; rated acceptable across age groups | Slavkova & Breitkreutz, 2015; Orlu et al., 2017 |
The table is the short version. Each row has real pharmacology behind it, so let me walk the ones that drive my formulation choices.
Where the dose goes. This is the row that matters most and the one marketing usually blurs. An ODT is swallowed after it disintegrates, so unless the molecule is unusually permeable, the dose behaves like any oral tablet once it reaches the gut. The contrast case I keep in mind is asenapine: Bartlett and van der Voort Maarschalk showed that when asenapine is held in the mouth it is absorbed across the mucosa, but when it is swallowed its oral bioavailability collapses to under 2 percent because of first-pass metabolism.8 That is a vivid reminder that the route, not just the speed of disintegration, decides how much dose survives.
Contact-time effect. The cleanest evidence that mucosal contact itself changes absorption comes from Grass and colleagues, who used microdosed midazolam to isolate the variable. Absolute bioavailability was 27.8 percent when the dose was swallowed as a drinking solution, and 66.1 percent after 100 seconds of buccal contact.7 The compound was the same; only the contact time changed. A film is built to capture some of that contact window. A disintegrating tablet, by design, gives it up as soon as the patient swallows.
Mechanical robustness. This is the practical row that I think gets underweighted. To disintegrate in seconds, many ODTs are compressed at low force and carry a porous internal matrix, which makes them fragile and friable; Ghourichay and colleagues note that handling friable, brittle ODTs is challenging and that they often need specialized dry, protective packaging.5 Slavkova and Breitkreutz, in their review of orodispersible forms for children and the elderly, contrast that fragility with the flexibility of films, which bend rather than shatter.3 A thin film tolerates a wallet or a pocket in a way a soft, porous tablet does not.
Acceptability and portability. Both forms are water-free and both are well tolerated. Orlu and colleagues found that orodispersible films were acceptable to caregivers and children, with 78 to 86 percent of caregivers rating their child's acceptance positively.9 I do not claim films beat tablets on acceptance across the board; ODTs are a mature, well-liked format. The portability edge is geometric: a flat, sealed film is simply easier to carry intact than a friable tablet in a blister.
What this means for MIHIYO products
For a product like Mood-Boost ODS, I am working with modest active loads where I want the option of mucosal contact, not just water-free convenience. That is the specific reason I chose a film over an orally disintegrating tablet. An ODT would have given me the no-water benefit, but it would have handed the entire dose to the gut the moment it disintegrated. With a film I can target a brief dissolution window and a defined contact geometry, which is the part of the design I actually have leverage over.
There is also a manufacturing reason. A film lets me hold the matrix mass and thickness tight from one unit to the next, and it survives normal handling without the friability problem that pushes many ODTs into special packaging. In early formulation thinking, the trade-off I kept returning to was robustness against load: films are elegant at low to moderate doses but get harder to build as the payload climbs. For the doses in our strips, that ceiling is not the binding constraint, so the film's advantages come without the penalty.
I want to be precise about the evidence. Every study cited here was run on independent clinical or formulation systems — midazolam, asenapine, pediatric film acceptability — not on MIHIYO products. We do not have a head-to-head human pharmacokinetic study comparing a MIHIYO strip with a matched ODT. What I am applying is route science and dosage-form engineering, honestly labeled as such. For more on why time-to-effect depends on the route, see our piece on onset time and Tmax, and for the disintegration side of the story, ODS vs tablets.
Where an ODT is the better choice
The film does not win every case, and I would not pretend otherwise. If a molecule is not absorbed across the mucosa at all, the contact-time advantage disappears, and an ODT is a perfectly rational, well-validated way to deliver a swallowed dose without water. The format has decades of clinical use behind it.
An ODT also handles higher payloads more gracefully than a thin film. When the dose is large, a tablet has more room to carry it than a film does before thickness, taste, and dissolution time start to fight each other. And some people simply prefer the feel of a tablet that melts to a film that sits on the tongue. Compliance is part of formulation reality; a technically tidy delivery path that a customer avoids is not better in practice.
So the honest framing is narrow. An ODT and an ODS both remove the glass of water. The film adds the possibility of directed mucosal contact and better physical robustness. Whether that possibility is worth anything depends entirely on the molecule and the dose.
The bottom line
In an oral dissolving strip vs orally disintegrating tablet comparison, the deciding question is not which form melts faster without water — both do that well. It is what happens in the seconds after. An ODT disintegrates and is swallowed, so its dose is absorbed in the gut; a film can hold part of the dose in mucosal contact, where contact time has been shown to more than double absolute bioavailability for a contact-sensitive molecule.7 The film is also more flexible and less fragile than a low-compression tablet.5 For MIHIYO Labs, that combination of route control and physical robustness is why our supplements are films, not disintegrating tablets.
References
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Orally Disintegrating Tablets. 2008. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/orally-disintegrating-tablets>
- Hoffmann EM, Breitenbach A, Breitkreutz J. Advances in orodispersible films for drug delivery. Expert Opin Drug Deliv. 2011;8(3):299-316. PMID: 21284577. DOI: 10.1517/17425247.2011.553217. <https://pubmed.ncbi.nlm.nih.gov/21284577/>
- Slavkova M, Breitkreutz J. Orodispersible drug formulations for children and elderly. Eur J Pharm Sci. 2015;75:2-9. PMID: 25736528. DOI: 10.1016/j.ejps.2015.02.015. <https://pubmed.ncbi.nlm.nih.gov/25736528/>
- Jacob S, Nair AB, Patil A, Boddu SHS. An Updated Overview of the Emerging Role of Patch and Film-Based Buccal Delivery Systems. Pharmaceutics. 2021;13(8):1206. PMID: 34452167. DOI: 10.3390/pharmaceutics13081206. <https://pubmed.ncbi.nlm.nih.gov/34452167/>
- Poursharifi Ghourichay M, Kiaie SH, Nokhodchi A, Javadzadeh Y. Formulation and Quality Control of Orally Disintegrating Tablets (ODTs): Recent Advances and Perspectives. Biomed Res Int. 2021;2021:6618934. PMID: 34977245. DOI: 10.1155/2021/6618934. <https://pubmed.ncbi.nlm.nih.gov/34977245/>
- Koner JS, Rajabi-Siahboomi A, Bowen J, Perrie Y, Kirby D, Mohammed AR. Conceptualisation, Development, Fabrication and In Vivo Validation of a Novel Disintegration Tester for Orally Disintegrating Tablets. Sci Rep. 2019;9(1):12467. PMID: 31462654. DOI: 10.1038/s41598-019-48859-x. <https://pubmed.ncbi.nlm.nih.gov/31462654/>
- Grass J, Rose P, Burhenne J, et al. Absolute Bioavailability of Microdosed Midazolam After Buccal Administration Is Dependent on Buccal Exposure Time. J Clin Pharmacol. 2021;61(4):532-539. PMID: 32976642. DOI: 10.1002/jcph.1751. <https://pubmed.ncbi.nlm.nih.gov/32976642/>
- Bartlett JA, van der Voort Maarschalk K. Understanding the Oral Mucosal Absorption and Resulting Clinical Pharmacokinetics of Asenapine. AAPS PharmSciTech. 2012;13(4):1110-1115. PMID: 22936407. DOI: 10.1208/s12249-012-9839-7. <https://pubmed.ncbi.nlm.nih.gov/22936407/>
- Orlu M, Ranmal SR, Sheng Y, Tuleu C, Seddon P. Acceptability of orodispersible films for delivery of medicines to infants and preschool children. Drug Deliv. 2017;24(1):1243-1248. PMID: 28856931. DOI: 10.1080/10717544.2017.1370512. <https://pubmed.ncbi.nlm.nih.gov/28856931/>
By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs. Focused on the R&D of high-bioavailability, fast-absorption oral dissolving strips.
0 comments